Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn’s Fistulas | Zendy

Amy L. Lightner | Zendy; Eric J. Dozois | Zendy; Allan B. Dietz | Zendy; Joel G. Fletcher | Zendy; Jessica Friton | Zendy; Greg W. Butler | Zendy; William A. Faubion | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn’s Fistulas

Author(s) -

Amy L. Lightner,

Eric J. Dozois,

Allan B. Dietz,

Joel G. Fletcher,

Jessica Friton,

Greg W. Butler,

William A. Faubion

Publication year - 2019

Publication title -

inflammatory bowel diseases

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izz215

Subject(s) - mesenchymal stem cell , refractory (planetary science) , medicine , crohn's disease , stem cell , disease , pathology , biology , astrobiology , genetics

Crohn's rectovaginal fistulizing disease remains notoriously difficult to treat. A phase I clinical trial to evaluate the safety and feasibility of a novel protocol using a mesenchymal stem cell (MSC)-coated Gore Bio-A fistula plug for the treatment of medically and surgically refractory Crohn's rectovaginal fistulas was conducted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research